Ionis' Ups and Downs: Partnership with Progenity, 70% Job Cuts at Akcea and More

Ionis Pharmaceuticals unleashed a string of news releases about activities at the company, including a partnership with Progenity and the launch of a Phase III trial for amyotrophic lateral sclerosis (ALS). It also announced that it was laying off almost 70% of the staff at Akcea Therapeutics as part of a reorganization. Let’s take a look at the company’s news.